

## Disclosures

### Personal Commercial (10)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Anthos	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Vascular Medicine</a>
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Vascular Medicine</a>
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Vascular Medicine</a>
Blue Cross Blue Shield of Michigan	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Vascular Medicine</a>
Boston Scientific	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Vascular Medicine</a>
Boston Scientific	Research/Research Grants	Significant (>= \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Bristol-Myers Squibb Company	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Vascular Medicine</a>
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Pulmonary Hypertension and Venous Thromboembolic</a>
Pfizer Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	<a href="#">Vascular Medicine</a>
Sanofi-Aventis	Consultant Fees/Honoraria	Modest (< \$5,000)	<a href="#">Vascular Medicine</a>

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Anticoagulation Forum	Officer, Director, Trustee, or other Fiduciary Role	None (\$0)	<a href="#">Other</a>

### Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
HI-PEITHO	Boston Scientific	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation (1)

Signed on 6/1/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

### Confidentiality, Disclosure and Assignment Agreement (1)

Signed on 6/1/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

### Embargo (1)

Signed on 6/1/2025  
[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

### On-Going Obligation Agreement (1)

Signed on 1/27/2026

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.